Literature DB >> 8324223

Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the Ig heavy chain gene.

Q M Ralph1, M J Brisco, D E Joshua, R Brown, J Gibson, A A Morley.   

Abstract

The Ig heavy chain (IgH) gene was used as a marker to investigate clonal succession and the origin of the neoplastic cell in multiple myeloma. The polymerase chain reaction (PCR) was used to amplify a section of the rearranged IgH gene at diagnosis and at progression in 21 patients who had exhibited a plateau phase. A monoclonal PCR product was seen for 16 of the patients and the product present at progression was of the same molecular weight as that at diagnosis. This finding suggests that the IgH rearrangement present at diagnosis and progression was the same. This was confirmed by sequencing the IgH gene in 10 patients. The IgH genes were found to be hypermutated at diagnosis, but no further hypermutation occurred during the course of the disease. The results provide evidence that the neoplastic cell in myeloma may originate as a memory B cell, plasmablast, or plasma cell, and suggest that progression beyond the plateau phase is not caused by clonal succession.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324223

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Marina Ramírez-Alvarado; Tammy L Price-Troska; Morie A Gertz; Rafael Fonseca
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

Review 2.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

3.  Assessment of IgH PCR strategies in multiple myeloma.

Authors:  R G Owen; R J Johnson; A C Rawstron; P A Evans; A Jack; G M Smith; J A Child; G J Morgan
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

Review 4.  Detection of minimal residual disease in multiple myeloma and acute leukaemia.

Authors:  M H Bakkus; N Juge-Morineau; J E van der Werff ten Bosch
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

5.  The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution.

Authors:  N Puig; I Conde; C Jiménez; M E Sarasquete; A Balanzategui; M Alcoceba; J Quintero; M C Chillón; E Sebastián; R Corral; L Marín; N C Gutiérrez; M-V Mateos; M González-Díaz; J F San-Miguel; R García-Sanz
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

Review 6.  Monitoring minimal residual disease in the bone marrow using next generation sequencing.

Authors:  Even H Rustad; Eileen M Boyle
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

7.  Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection.

Authors:  R G Owen; A P Haynes; P A Evans; R J Johnson; A C Rawstron; G McQuaker; G M Smith; M C Galvin; D L Barnard; N H Russell; J A Child; G J Morgan
Journal:  Clin Mol Pathol       Date:  1996-04

8.  Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.

Authors:  B C Millar; J B Bell; R L Powles
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.